Some major health insurers, including Aetna, WellPoint and Humana, have reduced patient cost-sharing for preventive drugs out of a growing realization that lowering cost-sharing increases patient compliance with drug therapies, improving outcomes and cutting the total cost of care.
Some major health insurers, including Aetna, WellPoint and Humana, have reduced patient cost-sharing for preventive drugs out of a growing realization that lowering cost-sharing increases patient compliance with drug therapies, improving outcomes and cutting the total cost of care.
This is partly the result of the federal healthcare reform law's requirement for first-dollar coverage of recommended preventive services. But it's also related to the growth of consumer-directed health plans with high deductibles. Payers have recognized that covering preventive drugs and other proven medical services below the deductible can make sense from a cost and quality perspective.
Some payers have reduced cost-sharing—including waiving deductibles and reducing or eliminating copayments and coinsurance—for drugs used for primary prevention, such as statins prescribed for patients with high blood cholesterol and lipids who have never had a heart attack. Others such as Aetna have gone further and reduced or waived cost-sharing for drugs used for secondary prevention, such as statins for patients who already have had a heart attack to reduce the chance of a reoccurrence.
Read the full story here: http://bit.ly/17CENfP
Source: Modern Healthcare
CMS released a final rule to help patients obtain Children’s Health Insurance Program (CHIP) coverage and issued a proposed rule to update Medicare payment policies and rates for inpatient rehabilitation facilities; debate over if gift card incentives are acceptable in health care marketing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Dr Chakra Chaulagain: PFS Is the "Bare Minimum," but OS Is Ideal for Choosing Between MM Therapies
March 28th 2024Response rates are important when choosing between therapies to treat multiple myeloma (MM), but improvement overall survival (OS) is the ideal, said Chakra Chaulagain MD, FACP, hematologist/oncologist, Maroone Cancer Center of Cleveland Clinic Florida.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Alopecia Areata Impacts Patient Perception, Quality of Life
March 27th 2024Patients with alopecia areata (AA) often perceive their hair loss as more severe than dermatologists do, leading to increased emotional and social problems. This study highlights the importance of understanding patient perception for better treatment and improved quality of life.
Read More